
|Articles|June 15, 2004
Topical cyclosporine can handle more than just dry eye disease
Any T cell-mediated disease found to benefit from this therapy without affecting other inflammatory pathways
Advertisement
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
Steven W. Pipe, MD, on Integrating Gene Therapy into Clinical Care for Hemophilia B
2
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL
3
Brian Lin, PhD, on Using Genetics, Biomarkers, and Clinical Trial Readiness to Enhance ALS Care
4
Data Roundup: December 2025 Features Updates from ASH and CTAD
5






























